Last reviewed · How we verify

Breath of Life International Pharma Ltd — Portfolio Competitive Intelligence Brief

Breath of Life International Pharma Ltd pipeline: 6 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
A3 A3 marketed Angiotensin receptor blocker AT1 receptor Cardiovascular
A5 A5 marketed SGLT2 inhibitor SGLT2 Diabetes
B4 B4 marketed monoamine oxidase inhibitor monoamine oxidase A Psychiatry
A1 A1 marketed SGLT2 inhibitor SGLT2 Diabetes
A4 A4 marketed CD4 receptor antagonist CD4 Infectious Disease
A2 A2 marketed Norepinephrine-dopamine reuptake inhibitor Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Asan Medical Center · 2 shared drug classes
  2. Pfizer · 2 shared drug classes
  3. AJU Pharm Co., Ltd. · 1 shared drug class
  4. Abbott · 1 shared drug class
  5. AceLink Therapeutics, Inc. · 1 shared drug class
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. Aciex Therapeutics, Inc. · 1 shared drug class
  8. AO GENERIUM · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Breath of Life International Pharma Ltd:

Cite this brief

Drug Landscape (2026). Breath of Life International Pharma Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/breath-of-life-international-pharma-ltd. Accessed 2026-05-17.

Related